

## **Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019**

---

**Strasbourg, France, May 9, 2019, 05:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies** announced that the Combined General Meeting (ordinary and extraordinary sessions) of Transgene's shareholders will be held on May 22, 2019, at 10 a.m. at the Company's registered office (400, boulevard Gonthier d'Andernach, 67400 Illkirch-Graffenstaden, France).

The notice of meeting, comprising the agenda and the draft resolutions was published in the *Bulletin des Annonces Légales Obligatoires* (BALO) n° 38 of March 29, 2019.

These notices include information on how to attend and vote at the General Meeting.

Information and documents pertaining to the Combined General Meeting are available in the Investors / General Shareholders Meeting section of Transgene's website [www.transgene.fr/AG2019](http://www.transgene.fr/AG2019).

- End -

### ***Notes to editors***

#### ***Contacts***

**Transgene:**

**Jean-Philippe Del**

+33 (0)3 88 27 91 04

[investorrelations@transgene.fr](mailto:investorrelations@transgene.fr)

**Media contacts:**

**Citigate Dewe Rogerson**

EU : David Dible/ Sylvie Berrebi

US : Marine Perrier-Barthez

+ 44 (0)20 7638 9571 / +1 424 341 9140

[transgene@citigatedewerogerson.com](mailto:transgene@citigatedewerogerson.com)

### **About Transgene**

Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical development, including TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B) and TG6002 (an oncolytic virus for the treatment of solid tumors). With its proprietary Invir.IO™, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.

*myvac*™, an individualized MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio. TG4050, the first candidate selected from the *myvac*™ platform, will enter the clinic for the treatment of ovarian cancer and head and neck cancer.

Additional information about Transgene is available at [www.transgene.fr](http://www.transgene.fr)

Follow us on Twitter: @TransgeneSA

### **Disclaimer**

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently underway, (ii) regulatory authorities will agree with the Company's further development plans for its therapies, or (iii) the Company will find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results and development.

For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risques") section of the Document de Référence, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website ([www.transgene.fr](http://www.transgene.fr)). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.